Review



ip experiment  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech ip experiment
    Ip Experiment, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ip experiment/product/Proteintech
    Average 93 stars, based on 11 article reviews
    ip experiment - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    93
    Proteintech ip experiment
    Ip Experiment, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ip experiment/product/Proteintech
    Average 93 stars, based on 1 article reviews
    ip experiment - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc ip experiment
    Ip Experiment, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ip experiment/product/Cell Signaling Technology Inc
    Average 99 stars, based on 1 article reviews
    ip experiment - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    90
    Epizyme Inc dykddddk ip/co-ip kit for co-ip experiments
    Dykddddk Ip/Co Ip Kit For Co Ip Experiments, supplied by Epizyme Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dykddddk ip/co-ip kit for co-ip experiments/product/Epizyme Inc
    Average 90 stars, based on 1 article reviews
    dykddddk ip/co-ip kit for co-ip experiments - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    SAS institute co-ip experiments
    Co Ip Experiments, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/co-ip experiments/product/SAS institute
    Average 90 stars, based on 1 article reviews
    co-ip experiments - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc chromatin immunoprecipitation chip experiment
    Oestrogen receptor 1 (ESR1) suppressed adipogenic differentiation of fibro/adipogenic progenitors (FAPs) by inhibiting transcription of peroxisome proliferator‐activated receptor gamma (PPARγ). (A) Bubble chart of GO analysis of up‐regulated and down‐regulated genes in FAPs from Esr1 knockout (KO) mouse when compared with those from Esr1 f/f mouse. Key GO terms were highlighted with red frames. (B) KEGG analysis of up‐regulated genes in FAPs from Esr1 KO mouse compared to those from Esr1 f/f mice. Key KEGG terms were highlighted with a red frame. (C) The sequence logo of potential ESR1 binding sites on the PPARγ promoter was predicted using JASPAR. (D) Scheme of construction of wild type (WT) and mutant pGL3‐PPARγ promoter reporter plasmids. (E, F) Protein levels and quantitative assessment of ESR1 and GAPDH after transfection with ESR1 overexpression (ESR1 OE) and vector (Vector) plasmids ( n = 3 per condition). (G) Quantitative assessment of luciferase activity after transfection with WT and mutant (Mut) pGL3‐PPARγ promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (H) Chromatin <t>immunoprecipitation</t> <t>(ChIP)‐qPCR</t> analysis for ESR1 binding to the PPARγ promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001, **** indicated p < .0001.
    Chromatin Immunoprecipitation Chip Experiment, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/chromatin immunoprecipitation chip experiment/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    chromatin immunoprecipitation chip experiment - by Bioz Stars, 2026-05
    97/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc chromatin immunoprecipitation experiment
    Oestrogen receptor 1 (ESR1) suppressed adipogenic differentiation of fibro/adipogenic progenitors (FAPs) by inhibiting transcription of peroxisome proliferator‐activated receptor gamma (PPARγ). (A) Bubble chart of GO analysis of up‐regulated and down‐regulated genes in FAPs from Esr1 knockout (KO) mouse when compared with those from Esr1 f/f mouse. Key GO terms were highlighted with red frames. (B) KEGG analysis of up‐regulated genes in FAPs from Esr1 KO mouse compared to those from Esr1 f/f mice. Key KEGG terms were highlighted with a red frame. (C) The sequence logo of potential ESR1 binding sites on the PPARγ promoter was predicted using JASPAR. (D) Scheme of construction of wild type (WT) and mutant pGL3‐PPARγ promoter reporter plasmids. (E, F) Protein levels and quantitative assessment of ESR1 and GAPDH after transfection with ESR1 overexpression (ESR1 OE) and vector (Vector) plasmids ( n = 3 per condition). (G) Quantitative assessment of luciferase activity after transfection with WT and mutant (Mut) pGL3‐PPARγ promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (H) Chromatin <t>immunoprecipitation</t> <t>(ChIP)‐qPCR</t> analysis for ESR1 binding to the PPARγ promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001, **** indicated p < .0001.
    Chromatin Immunoprecipitation Experiment, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/chromatin immunoprecipitation experiment/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    chromatin immunoprecipitation experiment - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    90
    BioCampus Cologne mass spectrometry for silac-ip experiments
    Oestrogen receptor 1 (ESR1) suppressed adipogenic differentiation of fibro/adipogenic progenitors (FAPs) by inhibiting transcription of peroxisome proliferator‐activated receptor gamma (PPARγ). (A) Bubble chart of GO analysis of up‐regulated and down‐regulated genes in FAPs from Esr1 knockout (KO) mouse when compared with those from Esr1 f/f mouse. Key GO terms were highlighted with red frames. (B) KEGG analysis of up‐regulated genes in FAPs from Esr1 KO mouse compared to those from Esr1 f/f mice. Key KEGG terms were highlighted with a red frame. (C) The sequence logo of potential ESR1 binding sites on the PPARγ promoter was predicted using JASPAR. (D) Scheme of construction of wild type (WT) and mutant pGL3‐PPARγ promoter reporter plasmids. (E, F) Protein levels and quantitative assessment of ESR1 and GAPDH after transfection with ESR1 overexpression (ESR1 OE) and vector (Vector) plasmids ( n = 3 per condition). (G) Quantitative assessment of luciferase activity after transfection with WT and mutant (Mut) pGL3‐PPARγ promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (H) Chromatin <t>immunoprecipitation</t> <t>(ChIP)‐qPCR</t> analysis for ESR1 binding to the PPARγ promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001, **** indicated p < .0001.
    Mass Spectrometry For Silac Ip Experiments, supplied by BioCampus Cologne, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mass spectrometry for silac-ip experiments/product/BioCampus Cologne
    Average 90 stars, based on 1 article reviews
    mass spectrometry for silac-ip experiments - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    Oestrogen receptor 1 (ESR1) suppressed adipogenic differentiation of fibro/adipogenic progenitors (FAPs) by inhibiting transcription of peroxisome proliferator‐activated receptor gamma (PPARγ). (A) Bubble chart of GO analysis of up‐regulated and down‐regulated genes in FAPs from Esr1 knockout (KO) mouse when compared with those from Esr1 f/f mouse. Key GO terms were highlighted with red frames. (B) KEGG analysis of up‐regulated genes in FAPs from Esr1 KO mouse compared to those from Esr1 f/f mice. Key KEGG terms were highlighted with a red frame. (C) The sequence logo of potential ESR1 binding sites on the PPARγ promoter was predicted using JASPAR. (D) Scheme of construction of wild type (WT) and mutant pGL3‐PPARγ promoter reporter plasmids. (E, F) Protein levels and quantitative assessment of ESR1 and GAPDH after transfection with ESR1 overexpression (ESR1 OE) and vector (Vector) plasmids ( n = 3 per condition). (G) Quantitative assessment of luciferase activity after transfection with WT and mutant (Mut) pGL3‐PPARγ promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (H) Chromatin immunoprecipitation (ChIP)‐qPCR analysis for ESR1 binding to the PPARγ promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001, **** indicated p < .0001.

    Journal: Clinical and Translational Medicine

    Article Title: Oestrogen suppresses the adipogenesis of fibro/adipogenic progenitors through reactivating the METTL3–ESR1‐mediated loop in post‐menopausal females

    doi: 10.1002/ctm2.70206

    Figure Lengend Snippet: Oestrogen receptor 1 (ESR1) suppressed adipogenic differentiation of fibro/adipogenic progenitors (FAPs) by inhibiting transcription of peroxisome proliferator‐activated receptor gamma (PPARγ). (A) Bubble chart of GO analysis of up‐regulated and down‐regulated genes in FAPs from Esr1 knockout (KO) mouse when compared with those from Esr1 f/f mouse. Key GO terms were highlighted with red frames. (B) KEGG analysis of up‐regulated genes in FAPs from Esr1 KO mouse compared to those from Esr1 f/f mice. Key KEGG terms were highlighted with a red frame. (C) The sequence logo of potential ESR1 binding sites on the PPARγ promoter was predicted using JASPAR. (D) Scheme of construction of wild type (WT) and mutant pGL3‐PPARγ promoter reporter plasmids. (E, F) Protein levels and quantitative assessment of ESR1 and GAPDH after transfection with ESR1 overexpression (ESR1 OE) and vector (Vector) plasmids ( n = 3 per condition). (G) Quantitative assessment of luciferase activity after transfection with WT and mutant (Mut) pGL3‐PPARγ promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (H) Chromatin immunoprecipitation (ChIP)‐qPCR analysis for ESR1 binding to the PPARγ promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001, **** indicated p < .0001.

    Article Snippet: The chromatin immunoprecipitation (ChIP) experiment was conducted with the SimpleChIP Plus Kit (CST, cat#9005S).

    Techniques: Knock-Out, Sequencing, Binding Assay, Mutagenesis, Transfection, Over Expression, Plasmid Preparation, Luciferase, Activity Assay, Chromatin Immunoprecipitation, ChIP-qPCR, Incubation, Standard Deviation

    Oestrogen receptor 1 (ESR1) enhanced expression of methyltransferase‐like 3 (METTL3) in turn by serving as a transcription factor in fibro/adipogenic progenitors (FAPs). (A, B) Dot blot and quantitative assessment of relative N6‐methyladenosine (m6A) methylation levels in FAPs from peri‐menopausal (Peri) and post‐menopausal patients (Post; n = 3 patients/group). (C, D) Dot blot and quantitative assessment of relative m6A methylation levels in FAPs from sham mouse (Control) and FAPs from ovariectomy (OVX) mouse ( n = 3 mice/group). (E) The sequence logo of potential ESR1 binding sites on the METTL3 promoter was predicted using JASPAR. (F) Scheme of wild type (WT) and mutant (Mut) pGL3‐METTL3 promoter reporter plasmids. (G, H) Protein levels and quantitative assessment of ESR1 and GAPDH in female FAPs transfected with vector (Vector) and ESR1 overexpression (ESR1 OE) plasmids ( n = 3 per condition). (I) Relative luciferase activity after transfection of WT and mutant (Mut) pGL3‐METTL3 promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (J) Chromatin immunoprecipitation (ChIP)‐qPCR for ESR1 binding to the METTL3 promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001.

    Journal: Clinical and Translational Medicine

    Article Title: Oestrogen suppresses the adipogenesis of fibro/adipogenic progenitors through reactivating the METTL3–ESR1‐mediated loop in post‐menopausal females

    doi: 10.1002/ctm2.70206

    Figure Lengend Snippet: Oestrogen receptor 1 (ESR1) enhanced expression of methyltransferase‐like 3 (METTL3) in turn by serving as a transcription factor in fibro/adipogenic progenitors (FAPs). (A, B) Dot blot and quantitative assessment of relative N6‐methyladenosine (m6A) methylation levels in FAPs from peri‐menopausal (Peri) and post‐menopausal patients (Post; n = 3 patients/group). (C, D) Dot blot and quantitative assessment of relative m6A methylation levels in FAPs from sham mouse (Control) and FAPs from ovariectomy (OVX) mouse ( n = 3 mice/group). (E) The sequence logo of potential ESR1 binding sites on the METTL3 promoter was predicted using JASPAR. (F) Scheme of wild type (WT) and mutant (Mut) pGL3‐METTL3 promoter reporter plasmids. (G, H) Protein levels and quantitative assessment of ESR1 and GAPDH in female FAPs transfected with vector (Vector) and ESR1 overexpression (ESR1 OE) plasmids ( n = 3 per condition). (I) Relative luciferase activity after transfection of WT and mutant (Mut) pGL3‐METTL3 promoter reporter plasmids in female FAPs transfected with ESR1 overexpression plasmid ( n = 3 per condition). (J) Chromatin immunoprecipitation (ChIP)‐qPCR for ESR1 binding to the METTL3 promoter in female FAPs under incubation with IgG or anti‐ESR1 antibodies ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), ns indicated no significant differences, * indicated p < .05, *** indicated p < .001.

    Article Snippet: The chromatin immunoprecipitation (ChIP) experiment was conducted with the SimpleChIP Plus Kit (CST, cat#9005S).

    Techniques: Expressing, Dot Blot, Methylation, Control, Sequencing, Binding Assay, Mutagenesis, Transfection, Plasmid Preparation, Over Expression, Luciferase, Activity Assay, Chromatin Immunoprecipitation, ChIP-qPCR, Incubation, Standard Deviation

    E2 reactivated methyltransferase‐like 3 (METTL3)–oestrogen receptor 1 (ESR1)‐mediated loop in female post‐menopausal fibro/adipogenic progenitors (FAPs). (A) Chromatin immunoprecipitation (ChIP)‐qPCR for ESR1 binding to the peroxisome proliferator‐activated receptor gamma (PPARγ) promoter in female FAPs incubated with IgG or anti‐ESR1 antibodies following 3‐day treatments with either DMSO (Control) or oestrogen (E2) ( n = 3 per condition). (B) ChIP‐qPCR for ESR1 binding to the METTL3 promoter in female FAPs incubated with IgG or anti‐ESR1 antibodies following 3‐day treatments with either DMSO (Control) or oestrogen (E2) ( n = 3 per condition). (C, D) The protein levels of ESR1 and METTL3 in female post‐menopausal FAPs treated with DMSO (Control) or oestrogen (E2) ( n = 3 per condition). (E, F) Oil Red O staining and quantitative assessment of female post‐menopausal FAPs treated with DMSO (Control) or oestrogen (E2) following 10 days of adipogenic differentiation ( n = 5 per condition). Red indicated Oil Red O, blue indicated DAPI and the merged images were shown. Scale bar, 50 µm. (g) The mRNA expression of adipogenic and lipogenic genes in female post‐menopausal FAPs treated with DMSO (Control) or oestrogen (E2) following 10 days of adipogenic differentiation ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), * indicated p < .05, ** indicated p < .01, *** indicated p < .001, **** indicated p < .0001.

    Journal: Clinical and Translational Medicine

    Article Title: Oestrogen suppresses the adipogenesis of fibro/adipogenic progenitors through reactivating the METTL3–ESR1‐mediated loop in post‐menopausal females

    doi: 10.1002/ctm2.70206

    Figure Lengend Snippet: E2 reactivated methyltransferase‐like 3 (METTL3)–oestrogen receptor 1 (ESR1)‐mediated loop in female post‐menopausal fibro/adipogenic progenitors (FAPs). (A) Chromatin immunoprecipitation (ChIP)‐qPCR for ESR1 binding to the peroxisome proliferator‐activated receptor gamma (PPARγ) promoter in female FAPs incubated with IgG or anti‐ESR1 antibodies following 3‐day treatments with either DMSO (Control) or oestrogen (E2) ( n = 3 per condition). (B) ChIP‐qPCR for ESR1 binding to the METTL3 promoter in female FAPs incubated with IgG or anti‐ESR1 antibodies following 3‐day treatments with either DMSO (Control) or oestrogen (E2) ( n = 3 per condition). (C, D) The protein levels of ESR1 and METTL3 in female post‐menopausal FAPs treated with DMSO (Control) or oestrogen (E2) ( n = 3 per condition). (E, F) Oil Red O staining and quantitative assessment of female post‐menopausal FAPs treated with DMSO (Control) or oestrogen (E2) following 10 days of adipogenic differentiation ( n = 5 per condition). Red indicated Oil Red O, blue indicated DAPI and the merged images were shown. Scale bar, 50 µm. (g) The mRNA expression of adipogenic and lipogenic genes in female post‐menopausal FAPs treated with DMSO (Control) or oestrogen (E2) following 10 days of adipogenic differentiation ( n = 3 per condition). Data were shown as mean ± standard deviation (SD), * indicated p < .05, ** indicated p < .01, *** indicated p < .001, **** indicated p < .0001.

    Article Snippet: The chromatin immunoprecipitation (ChIP) experiment was conducted with the SimpleChIP Plus Kit (CST, cat#9005S).

    Techniques: Chromatin Immunoprecipitation, ChIP-qPCR, Binding Assay, Incubation, Control, Staining, Expressing, Standard Deviation